Korean J Urol.  1995 Aug;36(8):815-818.

The Gleason Score and the Change of Serum PSA after Maximum Androgen Blocking in Patients with Metastatic Prostate Cancer

• Lee DH
• Hong SJ
• Chung BH

Abstract

The prostate specific antigen(PSA) has the most available clinical value in monitoring the disease status and treatment response, especially in patients with advanced metastatic adenocarcinoma of prostate. Between March 1992 and May 1994, 22 patients with newly diagnosed metastatic prostate cancer received gonadotropin-releasing hormone analogue monthly and antiandrogen daily. The 15 patients whose serum PSA levels were normalized within the first 3 months had serum PSA level of 71.3+/-22.7 ng/ml at the time of diagnosis and their Gleason score was 6.2+/-1.3. The other 7 whose serum PSA levels were not normalized even after hormonal treatment, had 75.6+/-39.1 ng/ml of serum PSA level at the time of diagnosis and their Gleason score was 8.71+/-0.98. There was not signifcantly different in PSA levels but in Gleason scores between the two groups at diagnosis. So the serum PSA level of patients with low Gleason score have a tendency to be normalized within 3 months of hormonal treatment. And we suggest that the normalization of serum PSA level after 3 months treatment might be the earliest and most highly correlated predictor of response or prognosis.

Keyword

Advanced prostate cancer; Gleason score; Prostate specific antigen; Hormonal therapy

MeSH Terms

Adenocarcinoma
Diagnosis
Gonadotropin-Releasing Hormone
Humans
Neoplasm Grading*
Prognosis
Prostate*
Prostate-Specific Antigen
Prostatic Neoplasms*
Gonadotropin-Releasing Hormone
Prostate-Specific Antigen